Measured immunoglobulin e in allergic bronchopulmonary aspergillosis treated with omalizumab

Journal of Asthma

Volumn 47, Issue 8, 2010, Pages 942-945

  Lin, Robert Y ^a,b   Sethi, Sonali ^a,b   Bhargave, Geeta A ^a  

^a ST VINCENT S HOSPITAL   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Aspergillosis; Asthma; IgE; Omalizumab

Indexed keywords

ALLERGEN; FLUTICASONE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; ITRACONAZOLE; MONTELUKAST; OMALIZUMAB; PREDNISONE; RAGWEED ANTIGEN; SALBUTAMOL; SALMETEROL; VORICONAZOLE; ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ARTICLE; ASPERGILLUS FUMIGATUS; ASTHMA; BRONCHIECTASIS; CASE REPORT; CORTICOSTEROID THERAPY; DANDER; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPERSENSITIVITY; HYPOXEMIA; IMMUNOTHERAPY; MALE; OXYGEN THERAPY; RAGWEED POLLEN; TREE; WHEEZING; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; BLOOD; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS FUMIGATUS; BRONCHIECTASIS; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED;

EID: 77957369672     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2010.491144     Document Type: Article

References (22)

1. Chang TW, Davis FM, Sun NC, MacGlashan DW Jr, Hamilton RG. Monoclonal antibodies specific for human IgE producing B-cells: a potential therapeutic for IgE-mediated allergic diseases. Biotechnology 1990; 9:122-126.
2. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacody-namics of omalizumab. Br J Clin Pharmacol. 2007; 63:548-561.
3. Hamilton RG. Accuracy of US Food and Drug Administration-cleared IgE antibody assays in the presence of anti-IgE (omalizumab). J Allergy Clin Immunol 2006; 117:759-766.
4. Hamilton RG, Marcotte GV, Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J Immunol Methods 2005; 303:81-91.
5. Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, Dockhorn RJ, Reimann J, Su JQ, Fick RB Jr, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100:110-121.
6. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110:685-692.
7. Brinkmann F, Schwerk N, Hansen G, Ballmann M. Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis. Allergy 2010; 65:134-135.
8. Randhawa I, Chin T, Nussbaum E. Resolution of corticosteroid-induced diabetes in allergic bronchopulmonary aspergillosis with omalizumab therapy: a novel approach. J Asthma 2009; 46:445-447.
9. Lebecque P, Leonard A, Pilette C. Omalizumab for treatment of ABPA exacerbations in CF patients. Pediatr Pulmonol 2009; 44:516.
10. Erratum in: Pediatr Pulmonol 2009; 44:943-944.
11. Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol 2008; 43:1249-1251.
12. Zirbes JM, Milla CE. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 2008; 43:607-610.
13. van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007; 62:276-277.
14. Quintás Vázquez LM, Ortiz Piquer M, Pérez de Llano LA. [Effective anti-immunoglobulin-E antibody treatment of a patient with allergic bronchopulmonary aspergillosis] [in Spanish]. Arch Bronconeumol. 2009; 45:207.
15. Dave S, Cherry WB, Maddox DE. Omalizumab therapy in evolving allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2007; 119:S211.
16. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110:685-692.
17. Stevens DA, Schwartz HJ, Lee JY, Moskovitz BL, Jerome DC, Catanzaro A, Bamberger DM, Weinmann AJ, Tuazon CU, Judson MA, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000; 342:756-762.
18. Patterson R, Greenberger PA, Radin RC, Roberts M. Allergic bron-chopulmonary aspergillosis: staging as an aid to management. Ann Intern Med 1982; 96:286-291.
19. Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010; 125:383-389.
20. Agarwal R. Allergic bronchopulmonary aspergillosis. Chest 2009; 135:803-826.
21. Bernstein DI, Wanner M, Borish L, Liss GM; Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004; 113:1129-1136.
22. Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ, et al. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 2009; 123:107-113.e3.